Prescription opioid use, illicit drug use, and sexually transmitted infections among participants from a community engagement program in North Central Florida, Journal of Substance Use, vol.22, issue.1, pp.90-95, 2017. ,
Recommandations AFEF pour l'élimination de l'infection par le virus de l'hépatite C en France, 2018. ,
Access to hepatitis C virus treatment: Lessons from implementation of strategies for increasing access to antiretroviral treatment, International Journal of Infectious Diseases: IJID, vol.70, pp.65-68, 2018. ,
LES ALD des bénéficiaires de la CMU-C. Points de repère, 2007. ,
Comparative profiles of men and women with opioid dependence: Results from a national multisite effectiveness trial, The American Journal of Drug and Alcohol Abuse, vol.37, issue.5, pp.313-323, 2011. ,
Natural history and management of hepatitis C: Does sex play a role?, The Journal of Infectious Diseases, vol.209, pp.81-85, 2014. ,
Usage de drogues et conséquences: quelles spécificités féminines? Tendances, 2017. ,
The national healthcare system claims databases in France, SNIIRAM and EGB: Powerful tools for pharmacoepidemiology, Pharmacoepidemiology and Drug Safety, vol.26, issue.8, pp.954-962, 2017. ,
Barriers to interferon-alpha therapy are higher in intravenous drug users than in other patients with acute hepatitis C, Journal of Hepatology, vol.42, issue.3, pp.323-328, 2005. ,
Rapid and large-scale implementation of HCV treatment advances in France, BMC Infectious Diseases, vol.17, issue.1, p.784, 2007.,
URL : https://hal.archives-ouvertes.fr/inserm-02048136
Accessing hepatitis C patients who are difficult to reach: It is time to overcome barriers, Journal of Viral Hepatitis, vol.19, issue.12, pp.829-835, 2012. ,
Gender differences in demographic and clinical characteristics of patients with opioid use disorder entering a comparative effectiveness medication trial, The American Journal on Addictions, vol.27, issue.6, pp.465-470, 2018. ,
Evolution de la dépense en part de complémentaire santé des bénéficiaires de la CMU-c analyse et prévision, Les rapports de l'IRDES (Irdes/Fonds CMU-c), 2018. ,
Methadone induction in primary care for opioid dependence: A pragmatic randomized trial, ANRS Methaville). PLoS One, vol.9, issue.11, p.112328, 2014.,
URL : https://hal.archives-ouvertes.fr/hal-01772534
Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: A multistage systematic review, The Lancet Global Health, vol.5, issue.12, pp.1192-1207, 2017. ,
Hepatitis C virus prevention and care for drug injectors: The French approach, Hepatology, Medicine and Policy, vol.3, 2018. ,
Are females who inject drugs at higher risk for HIV infection than males who inject drugs: An international systematic review of high seroprevalence areas, Drug and Alcohol Dependence, vol.124, issue.1-2, pp.95-107, 2012. ,
HIV infection among persons who inject drugs: Ending old epidemics and addressing new outbreaks, AIDS, issue.6, pp.815-826, 2016. ,
Are targeted treatment recommendations in chronic hepatitis C tailored to diagnostic methods of fibrosis, Journal of Hepatology, vol.66, issue.2, pp.304-312, 2017. ,
Dual HIV risk and vulnerabilities among women who use or inject drugs: No single prevention strategy is the answer, Current Opinion in HIV and AIDS, vol.7, issue.4, pp.326-331, 2012. ,
Higher incidence of HCV in females compared to males who inject drugs: A systematic review and meta-analysis, Journal of Viral Hepatitis, vol.24, issue.2, pp.117-127, 2017. ,
The effect of female sex on hepatitis C incidence among people who inject drugs: Results from the international multicohort InC3 collaborative, Clinical Infectious Diseases, vol.66, issue.1, pp.20-28, 2018. ,
, France country drug report, 2018.
Gender differences in sexual and injection risk behavior among active young injection drug users in San Francisco (the UFO Study), vol.80, pp.137-146, 2003. ,
Access to care for vulnerable populations. Soins -La revue de référence infirmière, vol.790, pp.14-18, 2014. ,
Elimination of hepatitis C virus infection among PWID: The beginning of a new era of interferon-free DAA therapy, The International Journal of Drug Policy, vol.47, pp.26-33, 2017. ,
Barriers associated with the treatment of hepatitis C virus infection among illicit drug users, Drug and Alcohol Dependence, vol.93, issue.1-2, pp.141-147, 2008. ,
, , 2019.
, Global, regional, and country-level estimates of hepatitis C infection among people who have recently injected drugs, Addiction, vol.114, issue.1, pp.150-166
, Prise en charge de l'hépatite C par les médicaments antiviraux à action directe (AAD), HAS, 2016.
, HAS -Commission de la Transparence -Rapport d'évaluation des antiviraux d'action directe dans le traitement de l'hépatite C. Actualisation, HAS, 2017.
Réduction des risques chez les usagers de drogues, 2010. ,
Uptake of hepatitis C treatment among people who inject drugs attending Needle and Syringe Programs in Australia, Journal of Viral Hepatitis, vol.21, issue.3, pp.198-207, 1999. ,
HIV, HCV, and health-related harms among women who inject drugs: Implications for prevention and treatment, Journal of Acquired Immune Deficiency Syndromes, issue.2, pp.176-181, 1999. ,
Race and gender differences in the use of direct acting antiviral agents for hepatitis C virus, Clinical Infectious Diseases, vol.63, issue.3, pp.291-299, 2016. ,
Social context, diversity and risk among women who inject drugs in Vietnam: Descriptive findings from a cross-sectional survey, Harm Reduction Journal, vol.12, p.35, 2015. ,
Australia on track to achieve WHO HCV elimination targets following rapid initial DAA treatment uptake: A modelling study, Journal of Viral Hepatitis, vol.26, issue.1, pp.83-92, 2019. ,
A qualitative study among injection drug using women in Rhode island: Attitudes toward testing, treatment, and vaccination for hepatitis and HIV, AIDS Patient Care and STDs, vol.22, issue.1, pp.53-64, 2008. ,
Barriers to health care access for low income families: A review of literature, Journal of Community Health Nursing, vol.35, issue.1, pp.28-37, 2018. ,
A systematic review of hepatitis C virus treatment uptake among people who inject drugs in the European Region, BMC Infectious Diseases, vol.14, p.16, 2014. ,
Historical epidemiology of hepatitis C virus (HCV) in select countries, Journal of Viral Hepatitis, vol.3, pp.4-20, 2015. ,
Latent classes of sexual risk behavior and engagement in outreach, intervention and prevention services among women who inject drugs across 20 US cities, Journal of Acquired Immune Deficiency Syndromes, vol.79, issue.3, pp.305-314, 1999. ,
Restrictions for reimbursement of interferon-free direct-acting antiviral drugs for HCV infection in Europe, The Lancet Gastroenterology & Hepatology, vol.3, issue.2, pp.125-133, 2018. ,
, , 2016.
, Hepatitis C treatment uptake among patients who have received opioid substitution treatment: A population-based study, PLoS One, vol.11, issue.11, p.166451
Individual and structural vulnerability among female youth who exchange sex for survival, The Journal of Adolescent Health, vol.49, issue.1, pp.36-41, 2011. ,
Précarité: accès aux soins, 2018. ,
Accès universel aux traitements innovants contre l'hépatite C, 2017. ,
More than just someone to inject drugs with: Injecting within primary injection partnerships, 2015. ,
, International Journal of Drug Policy, vol.72, pp.61-68, 2019.
, Drug and Alcohol Dependence, vol.156, pp.275-281
Intimate injection partnerships are at elevated risk of high-risk injecting: a multi-level longitudinal study of HCV-serodiscordant injection partnerships in, PLoS One, vol.9, issue.10, p.109282, 2014. ,
OFDT. Accueil addictologique et médicosocial de femmes toxicodépendantes, 2010. ,
, Women who inject drugs: A review of their risks, experiences and needs, NDARC, 2010.
Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: Results of systematic reviews, Lancet, vol.378, issue.9791, pp.571-583, 2011. ,
, Tableau de bord TSO 2015, 2015.
Antiviraux dits à action directe dans l'hépatite C: en ville aussi, vol.38, pp.420-421, 2018. ,
Increased uptake of HCV testing through a community-based educational intervention in difficult-to-reach people who inject drugs: Results from the ANRS-AERLI study, PLoS One, vol.11, issue.6, p.157062, 2016.,
URL : https://hal.archives-ouvertes.fr/inserm-01994924
Disparities in direct acting antivirals uptake in HIV-hepatitis C co-infected populations in Canada, Journal of the International AIDS Society, issue.3, p.20, 2017. ,
Modelling the elimination of hepatitis C as a public health threat in Iceland: A goal attainable by 2020, Journal of Hepatology, vol.68, issue.5, pp.932-939, 2018. ,
Early successes in an open access, provincially funded hepatitis C treatment program in Prince Edward Island, Annals of Hepatology, vol.16, issue.5, pp.749-758, 2017. ,
Disparities in uptake of direct-acting antiviral therapy for hepatitis C among people who inject drugs in a Canadian setting, Liver International, 2019. ,
Barriers to and facilitators of hepatitis C testing, management, and treatment among current and former injecting drug users: A qualitative exploration, AIDS Patient Care and STDs, vol.24, issue.12, pp.753-762, 2010. ,
Gender differences in seeking care for hepatitis C in Australia, Journal of Substance Use, vol.12, issue.1, pp.59-70, 2007. ,
, Women's voices experiences and perceptions of women who face drug-related problems in Europe, The European Monitoring Centre fro Drugs and Drug Addiction, 2009.
Higher risk of incident hepatitis C virus among young women who inject drugs compared with young men in association with sexual relationships: A prospective analysis from the UFO Study cohort, BMJ Open, vol.4, issue.5, p.4988, 2014. ,
Knowledge and barriers associated with assessment and treatment for hepatitis C virus infection among people who inject drugs, Drug and Alcohol Review, issue.7, pp.918-924, 2012. ,
Value of a national administrative database to guide public decisions: From the système national d'information interrégimes de l'Assurance Maladie (SNIIRAM) to the système national des données de santé (SNDS) in France, vol.65, pp.149-167, 2017. ,
, Combating hepatitis B and C to reach elimination by 2030. Advocacy Brief, WHO, 2016.
, WHO International classification of diseases (ICD, WHO, 2018.